Avamys vs targeted action

Not a healthcare professional? Visit the GSK Nigeria Public website

For Nigeria Healthcare Professionals resident in Nigeria

Not a healthcare professional? Visit the GSK Nigeria Public website.

This site contains promotional material.

For Nigeria Healthcare Professionals resident in Nigeria

This site contains promotional material.

Report adverse event

Menu

Close

Basket

User logged in

Overlay Text

Visit our Public site

Event Registration successful

You now have sucesfully register for the event and you can also access the latest updates, events and resources.

In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number.

Account activated – pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

Event registration completed - pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We'll send you and email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.

Account activated - pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy the public content on our website

Event Account activated - pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy the public content on our website

In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.

already registered

X »

$previewUrl

Anoro Ellipta 20 mcg

has been lorem added to your basket

View Basket

Content Path:/content/cf-pharma/health-hcpportal/en_NG/hcp/home

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Popup

Targeted action with Avamys

FF has the highest glucocorticoid receptor affinity and the strongest tissue binding compared to other INCS* 1–4

Glucocorticoid receptor affinity 1(in human lung tissue in vitro)

Bud: Budesonide; FF: Fluticasone Furoate; FP: Fluticasone Propionate; INCS: Intranasal

Corticosteroid; MF: Mometasone Furoate; TCA: Triamcinolone

Longer tissue retention of Avamys (FF) enhances its duration of action 3

Retention of glucocorticoids 4

In vitro data – clinical significance is unknown

Pharmacodynamic profile of Avamys

Watch the video to find out more.

*Vs fluticasone propionate, budesonide, mometasone furoate and ciclesonide.

AR: allergic rhinitis; FF: fluticasone furoate; INCS: intranasal corticosteroids.

References

Villa E, Magnoni MS, Micheli D, Canonica GW. A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother 2011;12(13):2107–2117.
Baumann D, Bachert C, Högger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540–1550.
Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54.
Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660–667.